

# Protective Immunity to VZV: The Role of Binding and Neutralizing Antibodies

Suthee Mangmee, Ph.D.

Viral Immunology Research Laboratory  
Department of Immunology  
Faculty of Medicine Siriraj Hospital  
Mahidol University


Email: [suthee.man@mahidol.edu](mailto:suthee.man@mahidol.edu)

**The 34th Annual Virology Association of Thailand Conference**  
Viruses across Life's Journey: Old, New, and Unforeseen  
17-18 Nov 2025

# Outline



- VZV and Associated Diseases
- VZV Antibodies: Current Knowledge and Knowledge Gaps
- Our Research to Bridge the Gaps
- Future Plan



# Varicella-Zoster Virus (VZV)

- **Family:** *Herpesviridae*
- **Key Features:**
  - Establish lifelong neuronal latency
- **Associated Diseases:**
  - Primary infection: Varicella (chickenpox)
  - Reactivation: Zoster



Chickenpox



Zoster



# Role of Antibodies (Ab) in VZV

## Clinical evidence: VZV Ab correlates with protection


Administration of varicella zoster immunoglobulin can:

- Prevent chickenpox in exposed children
- Reduce post-herpetic neuralgia in adults by 50%


Lower VZV antibody levels are associated with:

- Higher chickenpox incidence/severity in children
- Higher zoster risk in adults

# Ab Response to VZV



Zerboni et. al (2014). Nature reviews microbiology, 12(3), 197-210.



## VZV glycoproteins (gp): Primary Ab target

### Binding antibodies (BAb):



- All Ab against VZV; indicating existing immunity, not protection

### Neutralizing antibodies (NAb):

- Subset of BAb blocking VZV entry and infection; confer protective immunity

### Binding to neutralizing antibodies ratio (B/N) reflects antibody quality

# VZV Serology and Incidence



Rimseliene G et. al (2016). BMC infectious diseases. 2016 Jun 7;16(1):254. Thongmee T et. al (2024). Human Vaccines & Immunotherapeutics. 2024 Dec 31;20(1):2367283.

## VZV seroprevalence and antibody level

- Rise with age
- Correlate with chickenpox incidence in children, but not with zoster among the elderly

# Bridging the Gaps: Our Research



## Knowledge gaps

Most VZV studies focus on BAb, not NAb or Ab quality, leaving the role of Ab in zoster protection unclear

The impact of aging on NAb or Ab quality (B/N) is unknown

## Hypothesis

Aging impairs NAb or Ab quality, increasing zoster risk despite high BAb levels

## Research questions

Does NAb or Ab quality better predict protection against zoster than BAb?

How does aging affect NAb or Ab quality to VZV?


## Objective

Assess VZV seroprevalence, BAb, NAb, and B/N among Thai elderly

# Research Methodology



Mahidol University  
Faculty of Medicine  
Siriraj Hospital



<https://webportal.bangkok.go.th/bangkoknoi/page/sub/21955>

## Study design:

- Community-based cross-sectional cohort

## Study population:

- 213 individuals, aged  $\geq 60$  years
- From 26 communities in Bangkok-Noi, near Siriraj Hospital

## Sample and data collection:

- Blood samples
- Demographic data and zoster history/vaccination

## Data and sample collection



**Registration → Screening → Physical Examination → Data & Blood Collection**

Siriraj Dept. Collaboration: Preventive and Social Medicine, Immunology, and Clinical Pathology

**Community outreach for participant screening and enrollment**

# Research Methodology



## Laboratory Assessment

### **BAb Measurement:**

- gp IgG ELISA (total VZV glycoproteins)
- gH/gL IgG ELISA (highly neutralizing epitope)

### **NAb Measurement:**

- Live-virus microneutralization assay

## Data Analysis

### **Seroprevalence Estimation**

### **Correlation Analysis**

- Assess relationships between age and levels of BAb, NAb, and the ratio of B/N



# Our Findings: Study Population

Characteristic	All participants (N= 213)
Age (years)	
Median (min–max)	69.0 (60.0–90.0)
Age group, N (%)	
60–69 years	111 (52.1)
70–79 years	79 (37.1)
≥ 80 years	23 (10.8)
Gender, N (%)	
Male	97 (45.5)
Female	116 (54.5)
HZ history, N (%)	
No	182 (85.4)
Yes	30 (14.1)
Unknown	1 (0.5)
HZ vaccination, N (%)	
No	206 (96.7)
Yes	3 (1.4)
Unknown	4 (1.9)

## Study Participants (n = 213)

**Age:** 60–90 years

**Gender:** no gender bias

**History of zoster:** 85.4% never had zoster

**Zoster vaccination:** 96.7% never vaccinated

- Vaccine not in national EPI; voluntary & costly → low coverage in high-risk group



# Our Findings: Elderly VZV Immunity

Serostatus	All participants (N=235)	Adult (N=22)	Elderly (N=213)	p-value
VZV gp IgG ELISA, N (%)				<0.001
Seropositive	229 (97.4)	19 (86.4)	210 (98.6)	
Borderline	2 (0.9)	0 (0.0)	2 (0.9)	
Seronegative	4 (1.7)	3 (13.6)	1 (0.5)	
VZV live virus MNT, N (%)				<0.001
Detectable NAb titer	148 (63.0)	6 (27.3)	142 (66.7)	
Undetectable NAb titer	87 (37.0)	16 (72.7)	71 (33.3)	

Undetectable NAb: <1:20 dilution shows no inhibition

## Seroprevalence:



- High as 98.6%
- Higher than adults

## NAb

- Only 66.7% of VZV-seropositive elderly have NAb


# Our Findings: Age-specific VZV-Ab

## Binding antibodies (BAb)




BAb (vZV gp IgG ELISA, gH/gL IgG ELISA) levels increases with age

## Neutralizing antibodies (NAb)



NAb level stable with age


# Our Findings: Age-specific VZV-B/N



- Increasing B/N ratio with age
- Increasing proportion of non-NAb to VZV-Ab with age in the elderly
- Reflecting reduced Ab quality

**At what age does Ab quality decline the most?**

# Our Findings: Age-specific VZV-B/N



## Increase in B/N among the elderly

- 2.3 fold-increase in 70-79 years
- 2.9 fold-increase in ≥80 years
- Elderly age ≥70 years may be the highest-risk group for zoster



# Our Findings vs Other Studies

## Consistent with previous studies

- VZV seroprevalence and Ab level (BAb) increase with age

## Additional insight from this study

- Ab quality declines with age; a higher proportion of non-NAb in the elderly
- Marked decline in Ab quality in elderly  $\geq 70$  years
- This age-related decline may explain the increased incidence of zoster in older adults



# Future Plan

## Bridging the population gap:

- **Thai HIV-infected individuals** (highly vulnerable to VZV)
  - Longitudinal characterizing antibody dynamics (quantity & quality) from childhood to adulthood

# Acknowledgement



Mahidol University  
Faculty of Medicine  
Siriraj Hospital



**Siriraj**  
**Research Development Fund**

**All community leaders and participants**



Assoc.Prof.Dr.Kobporn Boonnak and staffs

**Department of  
Preventive and Social Medicine**


Prof.Prasert Assantachai and all staffs

**Department of Immunology**

Prof.Dr.Tararaj Dharakul,  
Assist.Prof.Dr.Jarupa Soongsathitanon,  
and all staffs

**Department of Clinical Pathology**

All staffs



Mahidol University  
Faculty of Medicine  
Siriraj Hospital

# THANK YOU

## Q&A

**The 34th Annual Virology Association of Thailand Conference**  
*Viruses across Life's Journey: Old, New, and Unforeseen*  
17-18 Nov 2025